Format

Send to

Choose Destination
Am J Cardiovasc Drugs. 2019 Apr;19(2):99-105. doi: 10.1007/s40256-018-00319-z.

Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.

Author information

1
Noninvasive Department of Cardiology, Onassis Cardiac Surgery Center, Syngrou Avenue 356, 17674, Athens, Greece. efidemer@otenet.gr.
2
Interventional Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
3
Interventional Cardiology and Cardiology Department, Mediterraneo Hospital, Athens, Greece.
4
Intensive Care Unit Department, Attikon University Hospital, Athens, Greece.
5
Noninvasive Department of Cardiology, Onassis Cardiac Surgery Center, Syngrou Avenue 356, 17674, Athens, Greece.

Abstract

Pulmonary arterial hypertension represents a devastating disease, causing progressive increase of pulmonary vascular resistance leading to right ventricular dysfunction and death. Therapeutic management has rapidly advanced in recent years due to improved understanding of pathophysiology and new drugs have been developed; however, survival remains poor. Oral agents as phosphodiesterase type V inhibitors, the soluble guanylyl cyclase stimulator riociguat, the prostacyclin receptor agonist selexipag and the endothelin receptor antagonists have each achieved evidence-based validation and are recommended for pulmonary arterial hypertension. Initial oral monotherapy or combination therapy is recommended for patients with low or intermediate risk according to each patient's risk stratification. Intravenous epoprostenol is a synthetic prostacyclin and the first drug approved for the disease. Although it represents the only treatment shown to reduce mortality, it is underused. Survival rates for patients treated with oral combination drug therapies are lower than those for patients treated with initial combination therapies including intravenous epoprostenol. This raises the interesting question of whether intermediate risk pulmonary arterial hypertension patients should be routinely introduced to therapies including intravenous epoprostenol rather than combination oral therapies.

PMID:
30671881
DOI:
10.1007/s40256-018-00319-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center